Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Pure tone audiometry and cerebral pathology in healthy older adults.

Parker T, Cash DM, Lane C, Lu K, Malone IB, Nicholas JM, James S, Keshavan A, Murray-Smith H, Wong A, Buchannan S, Keuss S, Sudre CH, Thomas D, Crutch S, Bamiou DE, Warren JD, Fox NC, Richards M, Schott JM.

J Neurol Neurosurg Psychiatry. 2019 Nov 7. pii: jnnp-2019-321897. doi: 10.1136/jnnp-2019-321897. [Epub ahead of print]

2.

Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.

Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, Houot M, Lista S, Cacciamani F, Potier MC, Bertrand A, Lamari F, Benali H, Mangin JF, Colliot O, Genthon R, Habert MO, Hampel H; INSIGHT-preAD study group.

Lancet Neurol. 2018 Apr;17(4):335-346. doi: 10.1016/S1474-4422(18)30029-2. Epub 2018 Feb 27. Erratum in: Lancet Neurol. 2018 Apr 25;:.

PMID:
29500152
3.

Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.

Bilgel M, An Y, Helphrey J, Elkins W, Gomez G, Wong DF, Davatzikos C, Ferrucci L, Resnick SM.

Brain. 2018 Aug 1;141(8):2475-2485. doi: 10.1093/brain/awy150.

4.

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.

Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, Maruff P, Salvado O, Ames D, Martins RN, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Lancet Neurol. 2016 Sep;15(10):1044-53. doi: 10.1016/S1474-4422(16)30125-9. Epub 2016 Jul 20.

PMID:
27450471
5.

Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.

Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, Vemuri P, Mielke MM, Roberts RO, Machulda MM, Senjem ML, Gunter JL, Rocca WA, Petersen RC.

Lancet Neurol. 2017 Jun;16(6):435-444. doi: 10.1016/S1474-4422(17)30077-7. Epub 2017 Apr 26.

6.

Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.

Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, Shaw LM, Decarli CS, Carmichael O, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2011 May;134(Pt 5):1479-92. doi: 10.1093/brain/awr049. Epub 2011 Apr 7.

7.

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative*.

Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.

8.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

9.

Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

Yau WW, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, Mowrey W, Sheu LK, Snitz BE, Weissfeld L, Gianaros PJ, Aizenstein HJ, Price JC, Mathis CA, Lopez OL, Klunk WE.

Lancet Neurol. 2015 Aug;14(8):804-813. doi: 10.1016/S1474-4422(15)00135-0. Epub 2015 Jun 29.

10.

Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.

Lane CA, Barnes J, Nicholas JM, Sudre CH, Cash DM, Parker TD, Malone IB, Lu K, James SN, Keshavan A, Murray-Smith H, Wong A, Buchanan SM, Keuss SE, Gordon E, Coath W, Barnes A, Dickson J, Modat M, Thomas D, Crutch SJ, Hardy R, Richards M, Fox NC, Schott JM.

Lancet Neurol. 2019 Oct;18(10):942-952. doi: 10.1016/S1474-4422(19)30228-5. Epub 2019 Aug 20.

11.

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.

Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2014 May;137(Pt 5):1550-61. doi: 10.1093/brain/awu043. Epub 2014 Mar 12.

12.

Hippocampal subfield volumes and pre-clinical Alzheimer's disease in 408 cognitively normal adults born in 1946.

Parker TD, Cash DM, Lane CAS, Lu K, Malone IB, Nicholas JM, James SN, Keshavan A, Murray-Smith H, Wong A, Buchanan SM, Keuss SE, Sudre CH, Modat M, Thomas DL, Crutch SJ, Richards M, Fox NC, Schott JM.

PLoS One. 2019 Oct 17;14(10):e0224030. doi: 10.1371/journal.pone.0224030. eCollection 2019.

13.

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.

Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1304-14. doi: 10.1007/s00259-016-3359-8. Epub 2016 Mar 22.

PMID:
27003417
14.

Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.

Yew B, Nation DA; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2017 Jul 1;140(7):1987-2001. doi: 10.1093/brain/awx112.

15.

Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].

Lin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov.

16.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

17.

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM.

Lancet Neurol. 2012 Dec;11(12):1057-65. doi: 10.1016/S1474-4422(12)70227-2. Epub 2012 Nov 6.

18.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

PMID:
21310725
19.

Audiometric evaluation in patients with Alzheimer's disease.

Villeneuve A, Hommet C, Aussedat C, Lescanne E, Reffet K, Bakhos D.

Eur Arch Otorhinolaryngol. 2017 Jan;274(1):151-157. doi: 10.1007/s00405-016-4257-1. Epub 2016 Aug 23.

PMID:
27554665
20.

Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.

Wu KY, Liu CY, Chen CS, Chen CH, Hsiao IT, Hsieh CJ, Lee CP, Yen TC, Lin KJ.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1067-76. doi: 10.1007/s00259-015-3291-3. Epub 2016 Jan 7.

PMID:
26739329

Supplemental Content

Support Center